Optimising COVID-19 Episode Identification Using Serology and PCR/Rapid Antigen Testing: Insights from the BRACE Trial

Dr Ellie McDonald, PhD[1], Dr Laure F Pittet, PhD[1,2,3], Prof Marc Bonten, PhD[4,5], A/Prof Anthony Byrne, PhD[6], Prof John Campbell, MD[7], Prof Julio Croda, PhD[8,9,10], Prof Margareth Pretti Dalcolmo, PhD[12], Prof Andrew Davidson, MD[13], Ms Glauce dos Santos, MSc[12], Ms Kaya Gardiner, MPH[1,14], A/Prof Amanda Gwee, PhD[2,11,15], Dr Bruno Araújo Jardim, MSc[16], Dr Marcus Vinícius Guimaraes Lacerda, PhD[17,18,19], Prof Michaela Lucas, MD[20,21,22,23], Prof David J Lynn, PhD[24,25], A/Prof Laurens Manning, PhD[23,26,27], Prof Helen S Marshall, MD[28], Prof Kirsten P Perrett, PhD[2,29,30], A/Prof Cristina Prat-Aymerich, PhD[4,5], Dr Marco AM Puga, PhD[9,10], Prof Peter C Richmond, MBBS[23,27,31], Dr Jesús Rodríguez-Baño, PhD[32,33], Dr Ushma Wadia, MBBS[23,27], Prof Adilia Warris, PhD[34,35], Prof Nicholas J Wood, PhD[36,37,38], Prof Nigel Curtis, PhD[1,2,11,‡], Dr Nicole L Messina, PhD[1,2,‡], and the *BRACE Trial Consortium Group*[†]

[‡] Co-last authors, equal contribution.
[†] Members of the *BRACE trial Consortium* are listed in the Supplementary Appendix

[1]Infectious Diseases Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia
[2]Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia.
[3]Immunology, Vaccinology, and Infectious Diseases Unit, Department of Paediatrics, Gynaecology and Obsterics, Faculty of Medicine, University of Geneva and University Hospitals of Geneva, Geneva, Switzerland.
[4]European Clinical Research Alliance on Infectious Diseases, Utrecht, the Netherlands
[5]Julius Center for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, the Netherlands.
[6]St Vincent's Hospital, Heart Lung Stream, Darlinghurst, Sydney Australia and The University of New South Wales, Faculty of Medicine, St Vincent's Clinical School, Sydney Australia.
[7]Exeter Collaboration for Academic Primary Care, University of Exeter Medical School, Exeter, United Kingdom.
[8]Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
[9]Fiocruz Mato Grosso do Sul, Fundação Oswaldo Cruz, Campo Grande, Brazil.
[10]Universidade Federal de Mato Grosso do Sul, Campo Grande, Brazil.
[11]Infectious Diseases, Royal Children's Hospital Melbourne, Parkville, Victoria, Australia.
[12]Centro de Referência Professor Hélio Fraga, ENSP/FIOCRUZ (Fundação Oswaldo Cruz), Rio de Janeiro, Brazil.
[13]Melbourne Children's Trial Centre, Murdoch Children's Research Institute, Parkville, Victoria, Australia.
[14]Research Operations, The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia.
[15]Antimicrobials Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia.
[16]Institute of Clinical Research Carlos Borborema, Doctor Heitor Vieira Dourado Tropical Medicine Foundation, Manaus, Brazil.
[17]Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Brazil.
[18]Instituto Leônidas & Maria Deane, Oswaldo Cruz Foundation, Ministry of Health, Manaus, Brazil.
[19]University of Texas Medical Branch, Galveston, TX, USA.
[20]Department of Immunology, Pathwest, Queen Elizabeth II Medical Centre, Nedlands, Western Australia, Australia.
[21]Department of Immunology, Perth Children's Hospital, Nedlands, Western Australia, Australia.
[22]Department of Immunology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
[23]School of Medicine, University of Western Australia, Perth, Western Australia, Australia
[24]Flinders Health and Medical Research Institute, Flinders University, Bedford Park, South Australia, Australia.

[25]Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.

[26]Department of Infectious Diseases, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.

[27]Wesfarmers Centre for Vaccines and Infectious Diseases, The Kids Research Institute, Nedlands, Western Australia, Australia

[28]Adelaide Medical School and Robinson Research Institute, The University of Adelaide and the Women's and Children's Research Centre, Women's and Children's Health Network, Adelaide, SA, Australia.

[29]Department of Allergy and Immunology, Royal Children's Hospital Melbourne, Parkville, Victoria, Australia.

[30]Population Allergy Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia.

[31]Department of Immunology and General Paediatrics, Perth Children's Hospital, Nedlands, Western Australia, Australia.

[32]Division of Infectious Diseases and Microbiology, Department of Medicine, Hospital Universitario Virgen Macarena, University of Seville, Biomedicines Institute of Seville-Consejo Superior de Investigaciones Científicas, Seville, Spain.

[33]CIBER de Enfermedades Infecciosas, Instituto de Salud Carloss III, Madrid, Spain.

[34]Department of Infectious Diseases, Great Ormond Street Hospital, London, UK.

[35]Medical Research Council Centre for Medical Mycology, Department of Biosciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, United Kingdom.

[36]Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.

[37]National Centre for Immunisation Research and Surveillance of Vaccine Preventable Disease, Westmead, New South Wales, Australia.

[38]Sydney Children's Hospital Network, Westmead, New South Wales, Australia.

Correspondence to: Prof Nigel Curtis, Department of Paediatrics, University of Melbourne, Royal Children's Hospital Melbourne, 50 Flemington Rd., Parkville, VIC 3052, Australia (nigel.curtis@rch.org.au, telephone +61 3 9345 6366).

Abstract

Background
Accurately identifying COVID-19 episodes was crucial during the early pandemic for evaluating interventions. Results from diagnostic tools like PCR, rapid antigen test (RAT), and serology are affected by factors such as timing of tests and vaccination status. The BRACE trial, which investigated the impact of BCG vaccination on COVID-19 prevalence among healthcare workers, developed a comprehensive algorithm integrating these diagnostic tools for illness episode classification.

Methods
In the BRACE trial, 3988 participants reported 5512 febrile/respiratory illness episodes and provided longitudinal blood samples over one year. SARS-CoV-2 diagnosis relied on a three-component algorithm: (1) a serology algorithm assessing anti- SARS-CoV-2 nucleocapsid antibody seroconversion, (2) a PCR/RAT algorithm, and (3) an episode interpretation algorithm combining serology and PCR/RAT results to categorise episodes as COVID-19, Not COVID-19, or Missing. The component algorithms also accounted for vaccination status and timing of testing relative to symptom onset to refine episode classifications.

Findings
Of 5512 illness episodes, 890 (16%) were classified as COVID-19, 3852 (70%) as not COVID-19, and 770 (14%) as missing. Compared to relying solely on PCR/RAT results, integrating serology in the algorithm reduced the proportion of missing classifications by more than half. Among the COVID-19 episodes, 89% were identified by positive PCR/RAT results, and the remaining 11% (with missing or negative PCR/RAT tests) were identified by serology. Discordance between PCR/RAT and serology occurred in 12.8% of episodes.

Interpretation
An algorithm integrating PCR/RAT and serology results in the context of test timing and vaccine status enabled the accurate identification of COVID-19 episodes and minimised the number of episodes that would otherwise have been classified as missing.

Key words: Algorithm, Case definition, COVID-19, PCR, Rapid antigen test, Lateral flow test, Sankey

Background

Accurate identification of COVID-19 episodes was critical for evaluating the efficacy of new or existing therapeutics during the early stages of the pandemic. The performance of key diagnostic tests for SARS-CoV-2, such as respiratory swab testing and serology, is influenced by the timing of testing relative to symptom onset as well as prior COVID-19 vaccinations.

In the BRACE trial, which investigated the effect of BCG vaccination on the prevalence of COVID-19 among healthcare workers, comprehensive symptom data were collected alongside SARS-CoV-2 testing.(1-3) Here, we describe the algorithm developed during the BRACE trial, intended to more precisely identify COVID-19 episodes using illness episode data and diagnostic test results.

To address the influence of timing relative to symptom onset on the accuracy of microbiological and serological tests, as well as the potential effects of prior COVID-19 vaccination on test results, a three-component interpretation algorithm was designed. This algorithm incorporated serological result interpretation, PCR/rapid antigen test (RAT) respiratory swab test interpretation, and finally episode classification to COVID-19, Not COVID-19 or Missing result illness categories.

This approach enabled evaluation of the sensitivity and specificity of PCR/RAT testing compared to serology for SARS-CoV-2, and the frequency of discordant results. Furthermore, the algorithm facilitated insights into the impact of its components on the accurate ascertainment of COVID-19 episodes.

Methods

The BRACE trial

The BRACE trial (NCT04327206) was a phase 3 international randomised controlled trial to assess the impact of BCG vaccination on the prevalence of COVID-19 among healthcare workers.(1-3) Primary and secondary outcomes relied on accurate ascertainment of incident cases of COVID-19 (the first day of a participant's first episode of COVID-19) and their distinction from episodes of illness which were not due to SARS-CoV-2 infection.

The trial was designed early in the COVID-19 pandemic, with recruitment starting in March 2020. Selection of COVID-19 symptoms to be collected and diagnostic tests for SARS-CoV-2 were informed by best practice and government policies at the time, with the expectation that new knowledge would become available over time.

Illness episode ascertainment

Participants were asked on a weekly basis about any recent illness symptoms using a custom-built smartphone app (Trial Symptom Tracker, WeGuide), direct communication (phone calls or text messages), or a combination of both. During illness episodes, symptoms were recorded daily, and participants were prompted to undergo SARS-CoV-2 respiratory swab testing using PCR (sourced via government testing centres) or RAT (self-administered). Additionally, more comprehensive questionnaires were administered at the start of the trial and quarterly throughout the follow-up period. These collected information about COVID-19-specific vaccinations (date and vaccine type). Blood samples were collected at baseline and at 3, 6, 9 and 12 months post-randomisation to measure anti–SARS-CoV-2 nucleocapsid (NCP) antibodies using the Roche Cobas Elecsys anti–SARS-CoV-2 assay, (4, 5) and conducted by the Victorian Infectious Diseases Reference Laboratory (VIDRL).

Seroconversion was defined as a cut-off index (COI) value of ≥1.0 as per manufacturer's instructions.(6, 7)

Algorithms

Serological interpretation algorithm

The serology algorithm produced one of four possible outcomes: Seroconversion, No seroconversion, Indeterminate or Missing (where a blood sample was unavailable). For each illness episode, the most recent blood sample collected at least seven days prior to symptom onset (pre-episode sample), and the first and second blood samples collected after symptom onset were identified. The NCP serology result from these samples were used in the serological interpretation algorithm. The algorithm considered key factors, including the timing of blood sample in relation to the illness episode, any prior administration of the CoronaVac (Sinovac Biotech) COVID-19 vaccine (a whole inactivated virus vaccine which can induce anti-NCP antibodies), and increases in anti-NCP antibody titre (in cases of positive-to-positive serology results). A detailed description of the serological algorithm is provided in Supplementary Figure 1.

PCR/RAT interpretation algorithm

The PCR/RAT interpretation algorithm yielded three possible outcomes: Positive, Negative, or No result. Both PCR and RAT positive results were considered confirmation of SARS-CoV-2 infection if the timing of the test fell within defined symptomatic illness parameters. Positive PCR test results were considered valid if the sample was tested within three days prior to 10 days (RAT) or 21 days (PCR) after the start, or within seven days from the end, of an illness episode. For a negative result, a negative PCR was considered a 'Negative result', however a negative RAT result was classified as 'No result' due to the lower sensitivity of RAT testing.(8) A detailed description of the PCR/RAT interpretation algorithm is provided in Supplementary Figure 2.

Episode interpretation algorithm

The episode interpretation algorithm produced three possible classifications for each illness episode: COVID-19, Not COVID-19 or Missing (which included episodes for which results were missing, or indeterminate). The results of the serological and PCR/RAT algorithms were combined to categorise illness episodes using the episode interpretation algorithm, detailed in Figure 1. Each episode was assessed based on the combined PCR/RAT result and serology result. Additional conditions were then applied which evaluated other tests and COVID-19 episode results within the same timeframe.

Results

These analyses were restricted to the 3988 participants recruited to the BRACE trial from May 2020 to April 2021 from Australia, The Netherlands, Spain, the UK and Brazil. Of these, 2559 participants reported at least one episode of illness in the year post-randomisation, with a total of 5512 episodes included.

Of the 5512 episodes, 890 (16%) were classified as COVID-19, 3852 (70%) as Not COVID-19, and 770 (14%) as Missing (Figure 1). Figure 2 illustrates the participant flow from the combined PCR/RAT result to the final episode classification. Supplementary Figure 3 details the participant flow from the pre-episode NCP serology result to the final episode interpretation.

Of the 890 episodes defined as COVID-19, 792 (89%) had a positive PCR or RAT test result. Serology results were concordant (seroconversion) in 375 (47.4%) episodes, discordant (no seroconversion) in 38 (4.8%), and Indeterminate or Missing in 379 (47.9%) (Figure 2). The remaining 98 COVID-19 episodes were comprised of 56 (6.3%) with a missing PCR/RAT result and 42 (4.7%) with a negative PCR result (Supplementary Figure 4). The discordant PCR/RAT and serology results were not attributable to post-episode NCP titres being just above the threshold for seroconversion (Figure 3). Further investigation of the post-episode NCP titres, based on the number of days between the episode start date and post-episode blood collection date for the seroconverted PCR negative and PCR/RAT positive episodes are shown in Supplementary Figure 5. Median post-episode NCP titres were higher in seroconverting episodes with negative PCR results compared to those with positive PCR/RAT results (median 62.2, IQR: 15.9–122.9 vs. 41.3, IQR: 14.3–101.4; p=0.3). Relevant to this, median time between episode onset and post-episode serological testing was higher in the negative PCR episode group compared to the positive PCR/RAT group (median 76.5 days, IQR: 33-102 days vs. 61 days, IQR: 37-82 days; p=0.1).

There were 305 episodes that had a negative RAT test. Of the RAT-negative episodes without a PCR result, 11/179 (6.2%) were categorised as COVID-19 on the basis of seroconversion (Supplementary Figure 6). In comparison, of the episodes without a PCR result, 56/858 (7.0%) were categorised as COVID-19 on the basis of seroconversion (Figure 3).

Among the 3852 episodes classified as not COVID-19 by the final episode algorithm, 3050 (77%) had a negative PCR result (Figure 2 & Supplementary Figure 3). Of these, 1622 (53.2%) had concordant negative serology and PCR results (Figure 2). Additionally, 1351 (44.3%) episodes had a missing NCP serology result, but a negative PCR result. The remaining 77 (2.5%) episodes were discordant (seroconversion with a negative PCR result). However, the positive NCP serology result in these cases was attributed to participants' other PCR- or RAT-positive episodes within the same timeframe. For the remaining 802 (20%) Not COVID-19 episodes with a missing PCR result, 744 had no seroconversion between pre- and post-episode blood samples. These episodes would have been classified as Missing if the trial had relied on PCR/RAT results only. In the remaining 58 (7.2%) episodes, participants seroconverted, but the episode algorithm attributed this to another PCR- or RAT-positive episode.

Of the 770 episodes classified as Missing in the final episode result, 738 (95.8%) had both missing or indeterminant serology and PCR/RAT results. Of the remaining 32 episodes, participants seroconverted but the episodes were categorised as Missing because the participants had multiple episodes with missing a PCR/RAT result within the same seroconversion timeframe. This precluded the attribution of the COVID-19 diagnosis to one of the episodes, which was problematic as the timing of episode onset was important for analysis.

At the participant level missing result episodes were similarly distributed between every combination of COVID-19 and Not COVID-19 episodes (Figure 4). The sequential distribution of COVID-19, Not COVID-19 and Missing result episodes for each participant in the study demonstrates the progression from algorithm processing to the final trial outcomes. It highlights the points at which participants were censored, which occurred at one of two events: their first COVID-19 episode or their first episode with a Missing result (Figure 5).

Discussion

The algorithms developed for the BRACE trial provided a novel and robust method for the classification of illness episodes and identification of COVID-19 cases during the pandemic. Unlike other studies that relied solely on PCR/RAT testing (9-11) or serological testing,(12) the BRACE algorithms combined these test results with real-world considerations, including the timing of symptom onset, vaccination status, immune response dynamics, and the longitudinal classification of multiple illness episodes.

Notably, most studies that relied exclusively on PCR/RAT and/or serology testing lacked a consistent approach using an algorithm,(13, 14) often classifying cases individually. By contrast, our three-step algorithm accounted for variations in the sensitivity and specificity of PCR/RAT and serology over time, alongside the effects of COVID-19 vaccination on serological results. Critically, this included accounting for the lower reliability of a negative RAT result due to its lower sensitivity and the impact of CoronaVac-induced anti-NCP antibodies.(8)

Post-hoc analysis showed that less than 10% of participants with RAT-negative, PCR-missing episodes seroconverted and were classified as COVID-19, while nearly 15% of participants with RAT-negative, PCR-missing episodes were excluded from primary analysis due to missing serological results. These findings could guide future decisions about RAT inclusion.

Discordance between PCR/RAT and serology test results was observed in a small proportion (11%) of episodes. Of these, 38 (5%) were PCR/RAT-positive episodes without seroconversion. Possible explanations for these cases include mild infections that did not elicit a systemic response, early waning of immunity, limitations in the sensitivity of serology, or false positive PCR/RAT. Conversely, a similar number, 42 (6%) episodes, were PCR-negative episodes with seroconversion. Possible explanations for these cases include inadequate swabbing, technical issues, participant reporting errors, and undetected asymptomatic infections during the interval between blood samples.

Serological testing proved especially valuable when PCR/RAT results were unavailable. Negative serology reclassified 744 episodes with missing PCR/RAT results as Not COVID-19 by demonstrating an absence of seroconversion. Additionally, serology alone identified 11% (98/890) of COVID-19 episodes in which the PCR/RAT result was negative or missing. Overall, the algorithm reduced the proportion of episodes for which classification would not be possible (and therefore be classified as missing) by more than half, from 30% (1628/5512) to 14% (770/5512), highlighting its efficacy in managing incomplete data.

The addition of serology to PCR/RAT testing involves considerable cost and resources, including staff, consumables, shipment, laboratory assays, and data management. However, this should be weighed against the benefits, which included in-person follow-ups that encouraged trial retention, enhanced data accuracy, clarified discordances, and the facilitation of additional research opportunities, such as additional immunological studies.(15-20)

Despite our best effort, our analyses are limited by several factors. First, our definition of symptomatic COVID-19 relied on the original case criteria, excluding non-febrile episodes without respiratory symptoms. Second, the timing and type of PCR/RAT testing were not standardised and varied depending on individual settings. Third, serological testing was done quarterly rather than at a consistent interval following illness episodes, which may have affected the detection of seroconversion. Finally, a proportion of illness episodes had incomplete data. However, it is among the COVID-19-related trials with the most complete data available.

The three-component algorithm developed in the BRACE trial has potential for application beyond COVID-19, for studying other infectious diseases such as influenza or respiratory syncytial virus. These diseases also require accurate longitudinal monitoring to track transmission, to assess vaccine efficacy, and to evaluate intervention and treatment outcomes. By integrating multiple diagnostic modalities and accounting for variations in test sensitivity and timing, the algorithm provides a robust methodology adaptable to diverse epidemiological scenarios. Furthermore, its scalability and adaptability make it especially valuable in resource-constrained settings, in which access to advanced diagnostics may be limited. Streamlined versions of the algorithm could focus on optimising available resources—for instance, prioritising serological testing in specific cohorts or timing PCR/RAT tests strategically—thereby enhancing diagnostic accuracy without requiring substantial additional infrastructure.

In summary, despite robust data collection efforts, longitudinal COVID-19 studies faced practical challenges, particularly during the early pandemic. Testing availability and participant adherence likely contributed to the 14% of episodes still classified as missing. Adding serological testing demanded substantial time, financial resources, and participant effort but effectively halved the number of unclassified episodes. This underscores the important role of algorithms in achieving comprehensive classification, particularly in complex real-world study settings.

Authors' Contributions

All authors contributed substantially to the BRACE trial. NC is the chief principal investigator of the BRACE trial. EMD did all the statistical analysis with substantial input from NLM, NC, and LFP. EMD wrote the first draft of the report with input from NLM, NC, and LFP, and all authors critically reviewed it. All authors had final responsibility for the decision to submit for publication. NC attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Declaration of Interest Statements

All authors have completed the Journal of Infection declaration of competing interest template. This trial is financially supported by the Foundations listed in the Funding section; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work. PR has received investigator-initiated research grants to his institution from Sanofi outside this work and has received institutional funding from GlaxoSmithKline and Sanofi for local and international lectures and from AstraZeneca, Clover Biopharmaceuticals, GlaxoSmithKline, Novavax, Sanofi, and Pfizer for participation in vaccine scientific advisory boards unrelated to this work. He has been an investigator in sponsored, multicentre vaccine trials for AstraZeneca, Moderna, Novavax, Pfizer, and Sanofi with funding to his institution. He is Chief investigator on an investigator led COVID-19 vaccine trial and institution has received funding from the Medical Research Future Fund. HSM has received investigator-initiated research grants to her institution from Sanofi and Pfizer outside this work. She has been an investigator in sponsored, multicentre vaccine trials for Iliad, Seqirus and Pfizer, with funding to her institution. She is a Chief investigator on an investigator led COVID-19 vaccine trial and institution has received funding from the Medical Research Future Fund.

Data sharing statement

Deidentified participant data and data dictionary are available to others on request and on completion of a signed data access agreement. Requests can be made in writing to braceresearch@mcri.edu.au.

Ethics Committee approval

The study was approved by the Royal Children's Hospital Melbourne Human Research Ethics Committee (No.62586); the protocol was approved by the ethics committee at each site and all participants provided informed consent. The trial was overseen by a steering committee and a data safety and monitoring board.

Acknowledgements

We thank the trial participants and site personnel who were involved in assisting the trial (detailed in the Supplementary File). AJ Vaccines (Copenhagen) for facilitating BCG vaccine supplies; Devon Freewheelers (UK) for UK transport; Catalent (UK) for drug management; Fiocruz Clinical Research Platform for coordination and monitoring of sites in Brazil; the Pharmacy, Pathology and Immunisation Service teams from The Royal Children's Hospital Melbourne, and the Orygen Group for their support. The trial is supported by the Bill & Melinda Gates Foundation [INV017302], the Minderoo Foundation [COV-001], Sarah and Lachlan Murdoch, the Royal Children's Hospital Foundation [2020-1263 BRACE Trial], Health Services Union NSW, the Peter Sowerby Foundation, SA Health, the Insurance Advisernet Foundation, the NAB Foundation, the Calvert-Jones Foundation, the Modara Pines Charitable Foundation, the UHG Foundation Pty Ltd, Epworth Healthcare and individual donors. The Murdoch Children's Research Institute (MCRI) leads the BRACE trial across 36 sites in five countries. It is supported by the Victorian Government's Operational Infrastructure Support Programme. NC is supported by a National Health and Medical Research Council (NHMRC) Investigator Grant (GNT1197117). LFP is supported by the Swiss National Science Foundation (Early Postdoc Mobility Grant, P2GEP3_178155).

Role of Funding Source

Figure 1. Episode interpretation algorithm: the detail

* Seroconverted episode "Not COVID-19" because another episode explains the seroconversion
** Seroconverted episode "Not COVID-19" because another episode may explain the seroconversion
# Seroconverted episode "Missing" as unable to say which episode should be COVID-19
‡ In the presence of a positive PCR / RAT test, the episode is COVID-19 and serological results disregarded

Figure 2. Episode interpretation outcome

Figure 3. Pre and post NCP titre serology results by PCR/RAT and episode result

Figure 4. Overall episode interpretation: COVID-19, Not COVID-19 and Missing outcome episodes per participant (n=2,559)

Figure 5. Sequential episode interpretation: COVID-19, Not COVID-19 and Missing outcome episodes per participant

Censored post 1st COVID-19 episode
* Censored post missing episode

References

1.   Pittet LF, Messina NL, Gardiner K, Orsini F, Abruzzo V, Bannister S, et al. BCG vaccination to reduce the impact of COVID-19 in healthcare workers: Protocol for a randomised controlled trial (BRACE trial). BMJ Open. 2021 Oct 28;11(10):e052101. PubMed PMID: 34711598. Pubmed Central PMCID: PMC8557250. Epub 20211028.

2.   Pittet LF, Messina NL, Orsini F, Moore CL, Abruzzo V, Barry S, et al. Randomized Trial of BCG Vaccine to Protect against Covid-19 in Health Care Workers. N Engl J Med. 2023 Apr 27;388(17):1582-96. PubMed PMID: 37099341.

3.   Pittet LF, Messina NL, McDonald E, Orsini F, Barry S, Bonten M, et al. Bacille Calmette-Guérin vaccination to prevent febrile and respiratory illness in adults (BRACE): secondary outcomes of a randomised controlled phase 3 trial. eClinicalMedicine. 2024;72.

4.   Bond KA, Williams E, Nicholson S, Lim S, Johnson D, Cox B, et al. Longitudinal evaluation of laboratory-based serological assays for SARS-CoV-2 antibody detection. Pathology. 2021 Oct;53(6):773-9. PubMed PMID: 34412859. Pubmed Central PMCID: PMC8289701. Epub 20210720.

5.   Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020 Apr;5(4):562-9. PubMed PMID: 32094589. Pubmed Central PMCID: PMC7095430. Epub 20200224.

6.   Elecsys® Anti-SARS-CoV-2. Immunoassay for the qualitative detection of antibodies against SARS-CoV-2. In: Ltd RDI, editor. 2020.

7.   Noble C ME, Nicholson S, Biering-Sørensen S, Pittet LF, Byrne AL, Croda J, Dalcolmo M, Lacerda M, Lucas M, Lynn DJ, Prat Aymerich C, Richmond PC, Warris A, Curtis N, Messina NL; BRACE Trial Consortium Group. . Characterising the SARS-CoV-2 nucleocapsid (N) protein antibody response. Journal of Infection. 2025.

8.   Mak GC, Cheng PK, Lau SS, Wong KK, Lau CS, Lam ET, et al. Evaluation of rapid antigen test for detection of SARS-CoV-2 virus. J Clin Virol. 2020 Aug;129:104500. PubMed PMID: 32585619. Pubmed Central PMCID: PMC7278630. Epub 20200608.

9.   Czajka H, Zapolnik P, Krzych L, Kmiecik W, Stopyra L, Nowakowska A, et al. A Multi-Center, Randomised, Double-Blind, Placebo-Controlled Phase III Clinical Trial Evaluating the Impact of BCG Re-Vaccination on the Incidence and Severity of SARS-CoV-2 Infections among Symptomatic Healthcare Professionals during the COVID-19 Pandemic in Poland-First Results. Vaccines (Basel). 2022 Feb 17;10(2). PubMed PMID: 35214772. Pubmed Central PMCID: PMC8879775. Epub 20220217.

10.   Upton CM, van Wijk RC, Mockeliunas L, Simonsson USH, McHarry K, van den Hoogen G, et al. Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trial. EClinicalMedicine. 2022 Jun;48:101414. PubMed PMID: 35582122. Pubmed Central PMCID: PMC9098089. Epub 20220512.

11.   Koekenbier EL, Fohse K, van de Maat JS, Oosterheert JJ, van Nieuwkoop C, Hoogerwerf JJ, et al. Bacillus Calmette-Guerin vaccine for prevention of COVID-19 and other respiratory tract infections in older adults with comorbidities: a randomized controlled trial. Clin Microbiol Infect. 2023 Jun;29(6):781-8. PubMed PMID: 36736662. Pubmed Central PMCID: PMC9892323. Epub 20230202.

12.   Dos Anjos LRB, da Costa AC, Cardoso A, Guimaraes RA, Rodrigues RL, Ribeiro KM, et al. Efficacy and Safety of BCG Revaccination With M. bovis BCG Moscow to Prevent COVID-19 Infection in Health Care Workers: A Randomized Phase II Clinical Trial. Front Immunol. 2022;13:841868. PubMed PMID: 35392074. Pubmed Central PMCID: PMC8981724. Epub 20220322.

13.   Faustman DL, Lee A, Hostetter ER, Aristarkhova A, Ng NC, Shpilsky GF, et al. Multiple BCG vaccinations for the prevention of COVID-19 and other infectious diseases in type 1 diabetes. Cell Rep Med. 2022 Sep 20;3(9):100728. PubMed PMID: 36027906. Pubmed Central PMCID: PMC9376308. Epub 20220815.

14.   Santos AP, Werneck GL, Dalvi APR, Dos Santos CC, Tierno P, Condelo HS, et al. The effect of BCG vaccination on infection and antibody levels against SARS-CoV-2-The results of ProBCG: a multicenter randomized clinical trial in Brazil. Int J Infect Dis. 2023 May;130:8-16. PubMed PMID: 36841502. Pubmed Central PMCID: PMC9972589. Epub 20230224.

15.   Dos Santos PCP, Messina NL, de Oliveira RD, da Silva PV, Puga MAM, Dalcolmo M, et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in adult Brazilian health-care workers: a nested clinical trial. Lancet Infect Dis. 2024 Feb 26. PubMed PMID: 38423021. Epub 20240226.

16.   Messina NL, Germano S, McElroy R, Bonnici R, Grubor-Bauk B, Lynn DJ, et al. Specific and off-target immune responses following COVID-19 vaccination with ChAdOx1-S and BNT162b2 vaccines-an exploratory sub-study of the BRACE trial. EBioMedicine. 2024 May;103:105100. PubMed PMID: 38663355. Pubmed Central PMCID: PMC11058726. Epub 20240424.

17.   Messina NL, Sperotto MG, Puga MAM, da Silva PV, de Oliveira RD, Moore CL, et al. Impact of vaccine platform and BCG vaccination on antibody responses to COVID-19 vaccination. Front Immunol. 2023;14:1172851. PubMed PMID: 37465688. Pubmed Central PMCID: PMC10352084. Epub 20230703.

18.   Messina NL, Germano S, McElroy R, Rudraraju R, Bonnici R, Pittet LF, et al. Off-target effects of bacillus Calmette-Guerin vaccination on immune responses to SARS-CoV-2: implications for protection against severe COVID-19. Clin Transl Immunology. 2022;11(4):e1387. PubMed PMID: 35573165. Pubmed Central PMCID: PMC9028103. Epub 20220422.

19.   Stevens NE, Ryan FJ, Messina NL, Blake SJ, Norton TS, Germano S, et al. No evidence of durable trained immunity after two doses of adenovirus-vectored or mRNA COVID-19 vaccines. J Clin Invest. 2023 Sep 1;133(17). PubMed PMID: 37471143. Pubmed Central PMCID: PMC10471164. Epub 20230901.

20.   Ryan FJ, Norton TS, McCafferty C, Blake SJ, Stevens NE, James J, et al. A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA and adenovirus vectored vaccines. Cell Rep Med. 2023 Mar 21;4(3):100971. PubMed PMID: 36871558. Pubmed Central PMCID: PMC9935276. Epub 20230217.